ProHance® (gadoteridol)

 

When Stability Matters 1, 2, 3, 4

 

ProHance® (gadoteridol) is a macrocyclic, non-ionic molecule chelated to a gadolinium ion, and it has a very low osmolality and viscosity 5.

 

Due primarily to its macrocyclic structure, ProHance® possesses high in vitro stability 2, 3.

 

Moreover, in recent clinical studies in patients undergoing total hip arthroplasty it has been shown that bone tissue retention of gadolinium was significantly higher in patients who received Omniscan than in those who received ProHance®. Approximately 2.5 times more gadolinium remained in femoral head bone after Omniscan than after ProHance® 4, 5.

 

The clinical experience with ProHance® exceeds 15 million doses administered worldwide 6.

ProHance® is a gadolinium based, macrocyclic, non-ionic MR contrast agent first introduced in 1992. Since its launch ProHance® has established a strong record of safety and efficacy with millions of doses administered worldwide 7. ProHance® has a high stability and the lowest osmolality among all contrast agents in its class, which maximize clinical utility and diagnostic confidence 5.

 

ProHance® is a non-ionic contrast agent that does not interfere with a number of serum assays, including serum calcium determination 8.

ProHance® provides low dissociation rate and high “in vivo” stability, reducing the risk of free gadolinium exposure 2.

ProHance® has low viscosity, reducing pressure during high flow rate power injections 5; also, it provides optimal injection comfort due to the low osmolality in case of very high rate of injection as in dynamic MR Imaging 5.

ProHance® has high stability in virtue of the high chelate strength.

 

An in vivo study in rodents has shown that ProHance® releases the least amount of Gd in the body compared to gadopentetate, gadodiamide and gadoterate 2.

Gibby et al., and White et al., showed that ProHance® leaves up to four times less gadolinium in human bones than gadodiamide 3.

 

ProHance® has a full line of packaging options including unique solutions to optimize dosing protocols, reduce contrast waste, and increase operational efficiencies.

ProHance® is also provided in large volumes (available in some markets) that increase dosing flexibility, minimize contrast waste and simplify inventory management 5.

Contact us


Please fill out the form below and we will get back to you.

By checking this box and clicking the submit button of this page, I certify that I am a healthcare professional, and give permission for Bracco Imaging S.p.A., or parties acting on its behalf, to contact me with information regarding Bracco Imaging S.p.A., products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Imaging S.p.A., except for the agents or representatives processing this request.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

DISCLAIMER

 

For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully reviem the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The local Summaries of Product Characteristics of the main Bracco Imaging products are available on line.

 

Impaired renal function

 

There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR <30ml/min/1.73m2). As there is a possibility that NSF may occur with ProHance, it should only be used in these patients after careful consideration. Haemodialysis shortly after ProHance administration in patients currently receiving haemodialysis may be useful at removing Prohance from the body.

 

There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.